VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms

J. Mortimer, R. M. Bukowski, J. Montie, J. S. Hewlett, Robert B Livingston

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Eleven patients with recurrent and/or resistant nonseminomatous germinal cell neoplasms refractory to conventional chemotherapy were treated with the combination VP16-213, cis-diamminedichloroplatinum, and adriamycin. One complete response, four partial responses which at surgery were benign teratomas, and six partial responses have been observed. Four patients are prolonged survivors (>18 months). The possibility that this regimen may offer true salvage for refractory patients exists. Incorporation of VP16-213 into initial treatment regimens for germinal cell neoplasms is warranted.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume7
Issue number2-3
DOIs
Publication statusPublished - 1982
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this